Minimally Invasive Coronary Artery Bypass Supported by Cangrelor

What this Trial Is About

Researchers are evaluating whether MIDCAB surgery, a minimally invasive heart bypass procedure, can be safely performed while patients receive a continuous infusion of cangrelor, a medicine that helps prevent blood clots. This study compares patients receiving cangrelor during surgery with historical patients who had the same surgery while on aspirin therapy, with or without prior cangrelor use. The goal is to determine if using cangrelor during MIDCAB surgery is safe and feasible without increasing bleeding risks or other complications. The study involves two groups: patients prospectively enrolled to undergo MIDCAB surgery while receiving continuous intravenous cangrelor infusion at 0.75 mcg/kg per minute, with prior oral antiplatelet therapies stopped and platelet function monitored daily; and historical control patients who underwent MIDCAB surgery under aspirin therapy with or without prior cangrelor bridging. The surgical procedure is performed at least 24 hours after cangrelor initiation with anticoagulation using unfractionated heparin monitored by activated clotting time. Data on perioperative safety, bleeding outcomes, laboratory values, and clinical events are collected. Participants are closely monitored throughout surgery and hospitalization, including assessments of platelet function, vital signs, ECG, cardiac biomarkers, and laboratory tests. Researchers collect data on bleeding during and after surgery, cardiac events, blood transfusions, ICU stay, chest tube output, renal function, and length of hospital stay. Safety monitoring continues from inclusion through discharge, with serious adverse events followed until resolved or stable. The study uses secure electronic data capture and quality assurance measures to ensure accurate data collection and analysis.

Minimally Invasive Coronary Artery Bypass Supported by Cangrelor